Analysts Set Elanco Animal Health Incorporated (NYSE:ELAN) Price Target at $23.78

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have earned an average rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, seven have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $23.7778.

Several equities research analysts have recently weighed in on ELAN shares. KeyCorp reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research report on Wednesday, December 10th. Morgan Stanley boosted their price target on Elanco Animal Health from $18.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Thursday, December 18th. Stifel Nicolaus upped their price target on Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Elanco Animal Health in a research note on Monday, December 22nd. Finally, Zacks Research cut shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th.

Insider Activity

In other Elanco Animal Health news, insider Rajeev A. Modi bought 4,500 shares of the company’s stock in a transaction dated Thursday, December 11th. The shares were acquired at an average cost of $21.33 per share, with a total value of $95,985.00. Following the completion of the transaction, the insider owned 123,082 shares in the company, valued at $2,625,339.06. The trade was a 3.79% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jeffrey N. Simmons purchased 22,000 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was acquired at an average price of $21.75 per share, for a total transaction of $478,500.00. Following the purchase, the chief executive officer owned 167,000 shares of the company’s stock, valued at approximately $3,632,250. This represents a 15.17% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have bought 43,450 shares of company stock worth $937,883. 0.89% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Elanco Animal Health

Several hedge funds and other institutional investors have recently bought and sold shares of the business. AlphaQuest LLC boosted its stake in shares of Elanco Animal Health by 13.7% during the 3rd quarter. AlphaQuest LLC now owns 5,953 shares of the company’s stock valued at $120,000 after buying an additional 718 shares during the last quarter. Jones Financial Companies Lllp boosted its holdings in shares of Elanco Animal Health by 15.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 6,065 shares of the company’s stock valued at $119,000 after buying an additional 798 shares during the period. MTM Investment Management LLC grew its holdings in shares of Elanco Animal Health by 5.5% during the second quarter. MTM Investment Management LLC now owns 15,268 shares of the company’s stock valued at $218,000 after purchasing an additional 800 shares during the last quarter. HighTower Advisors LLC grew its stake in Elanco Animal Health by 7.0% during the 1st quarter. HighTower Advisors LLC now owns 12,445 shares of the company’s stock worth $131,000 after buying an additional 810 shares during the last quarter. Finally, US Bancorp DE grew its position in shares of Elanco Animal Health by 1.9% during the third quarter. US Bancorp DE now owns 43,810 shares of the company’s stock worth $882,000 after acquiring an additional 824 shares during the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Price Performance

ELAN opened at $22.61 on Friday. Elanco Animal Health has a 52-week low of $8.02 and a 52-week high of $23.70. The company has a 50 day moving average of $22.10 and a two-hundred day moving average of $18.70. The company has a market cap of $11.23 billion, a P/E ratio of 376.81, a P/E/G ratio of 3.46 and a beta of 1.86. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same quarter in the previous year, the business posted $0.13 EPS. The business’s quarterly revenue was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. On average, analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.